REGN5381 in Adult Participants With Heart Failure With Reduced Ejection Fraction

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Heart Failure

In brief

This study is researching an experimental drug called REGN5381 (called "study drug"). The study is focused on patients with heart failure with reduced ejection fraction (ie, the heart is not functioning as well as it should). The aim of the study is to see how safe, tolerable, and effective the study drug is. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)

Key facts

Study ID
NCT06237309
Run by
Regeneron Pharmaceuticals
People needed
89
Starts
2024-04-11
Expected to finish
2025-12-29
Last updated by the study team
2026-01-14

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.